EVALUATION OF THE SLEEP-PROMOTING ACTIVITY OF HERBAL FORMULATIONS IN MOUSE MODEL OF CAFFEINE-INDUCED DISRUPTION OF BARBITURATE-INDUCED SLEEP

EVALUATION OF THE SLEEP-PROMOTING ACTIVITY OF HERBAL FORMULATIONS IN MOUSE MODEL OF CAFFEINE-INDUCED DISRUPTION OF BARBITURATE-INDUCED SLEEP.


1.0 TEST SYSTEM DETAILS:

Species: Mus musculus (Mice)

Strain : Balb/c or Swiss Albino

Age: 4-5 weeks

Sex: Male

No. of animals: 10 /Group

Total animals: 70

2.0 TEST ARTICLES DETAILS

RS1: HB-1


3.0 ALLOCATION OF GROUPS:





   Group No.

Group Description

Sleep disrupting  agent administered

A sleep-inducing agent administered

Treatment administered

Dose Volume and Route

G1

Normal Control

Normal Saline administered by intraperitoneal route (i.p.),

Pentobabitone-45 mg/kg, i.p., single dose

0.5% MC, p.o., b.i.d.

10 ml/kg, p.o.

G2

Disease Control

 

 

 

Caffeine-50 mg/kg, i.p., single dose

 

 

 

 

Pentobabitone-45 mg/kg, i.p., or thiopentone-50 mg/kg, i.p.,  single dose

0.5% MC, p.o., b.i.d.

G3

Reference Control

Alprazolam 0.3 mg/kg, once only

G4

Treated with a low dose of HB1

HB1: 10-30 mg/kg, b.i.d.  in 0.5% MC

G5

Treated with intermediate dose 1 of HB1

HB2: 30-100 mg/kg, mg/kg, b.i.d. in 0.5% MC

G6

Treated with intermediate dose 2 of HB1

HB3: 100-300 mg/kg,   b.i.d. in 0.5% MC

G7

Treated with high dose of HB1

HB4: 300-1000 mg/kg,  b.i.d. in 0.5% MC


Abbreviations: MC-Methyl Cellulose, p.o.-per os. q.d.: quaque die; bid: bis in die, i.p.-Intraperitoneal


4.0 METHOD:

· Healthy animals will be selected for the study, randomized based on body weight, and assigned to 7 groups of 10 animals each.

· Animals of Group G1 will be designated as normal-control and administered 0.5% MC, p.o., b.i.d.

· Disease control animals (assigned to group G2) will receive 0.5% MC, p.o., b.i.d.

· Animals of group G3 will be treated with reference drug alprazolam at the dose of 0.3 mg/kg, p.o.

· Animals of group G4-G7 will be treated with HB1 at different dose levels ranging from 10-1000 mg/kg, b.i.d.

· Compound administration will be initiated 3 days before the sleep test.

· On day 3 the animals will be kept fasting for 24 hours

· On day 4, half an hour after administration of test articles, caffeine will be injected into the animals at the dose of 50 mg/kg, through the intraperitoneal route

· Subsequently, after 30 minutes of caffeine administration mice will either receive pentobarbitone at the dose of 45 mg/kg injected intraperitoneally or thiopentone administered intraperitoneally at the dose of 50 mg/kg administered intraperitoneally.

· Sleep latency (time taken for the loss of righting reflex) and sleep duration will be recorded for all the groups.

· Any animal that does not sleep within 15 minutes post barbiturate injection will be excluded from the study.

· After completion of the sleep test, animals will be sacrificed under an overdose of thiopentone anesthesia. Immediately after the animal dies, the brain will be excised, weighed, and stored at -80°C for molecular analysis.

5.0 PARAMETERS TO BE EVALUATED:

· Body weight

· Brain weight

· Evaluation of sleep latency and sleeping time

· Gene expression analysis by real-time PCR: GABAA, GABAB, and 5HT1A in brain tissue.

6.0 REFERENCE(S):

1. Yejin Ahna. et al. Sleep-promoting activity of lotus (Nelumbo nucifera) rhizome water extract via GABAA receptors. Pharmaceutical Biology, vol. 60, no.1, 1341–1348 (2022).

2. Ning Mou., Study on the hypnotic effect of rare protopanaxadiol-type and protopanaxatriol-type ginsenosides. RSC Adv., 9, 20483 (2019).

3. Rui Shi. et al. Loganin Exerts Sedative and Hypnotic Effects via Modulation of the Serotonergic System and GABAergic Neurons. Frontiers in Pharmacology. Vol. 10, 409 (2019).

4. Jae Joon Choi., et al. Gastrodiae Rhizoma Ethanol Extract Enhances Pentobarbital-Induced Sleeping Behaviors and Rapid Eye Movement Sleep via the Activation of GABA-ergic Transmission in Rodents. Evidence-Based Complementary and Alternative Medicine. 426843 (2014).

5. Yong-Hyun Ko. et al. Evodiamine Reduces Caffeine-Induced Sleep Disturbances and
Excitation in Mice. Biomol Ther 26(5), 432-438 (2018).


                                                                END OF THE DOCUMENT



SHARE

Owner

Hi. I’m Writer of Researchsop.com. ’ ’ Please share these SOPs to all concern pharma people for their development. I like to fullfill the need of curious people. These things inspire me to make things looks better.

  • Image
  • Image
  • Image
  • Image
  • Image
    Blogger Comment
    Facebook Comment

0 comments:

Post a Comment